Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized, Double-blinded, Double-dummy, Active-controlled, Multi-center Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of KW21052 for 8 Weeks Compared to Pregabalin (Lyrica) in the Diabetic Patients With Neuropathic Pain

NCT01863810 is registered in ClinicalTrials.gov with KunWha Pharmaceutical Co., Ltd. as lead sponsor.

NCT NCT01863810
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01863810 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized, Double-blinded, Double-dummy, Active-controlled, Multi-center Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of KW21052 for 8 Weeks Compared to Pregabalin (Lyrica) in the Diabetic Patients With Neuropathic Pain
Lead sponsor
KunWha Pharmaceutical Co., Ltd.
Phase
Phase 3
Overall status
Unknown status
Start date
August 31, 2013
Completion date
October 31, 2014
Enrollment
394 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

diabetic neuropathy